Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 23, 2017 16:05 ET | Source: Nivalis Therapeutics, Inc.

Nivalis Therapeutics Announces Results from Phase 2 Clinical Trial of Cavosonstat Added to Ivacaftor for Treatment of Cystic Fibrosis

BOULDER, Colo., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a pharmaceutical company historically focused on developing innovative solutions for people with...
February 13, 2017 16:05 ET | Source: Nivalis Therapeutics, Inc.

Nivalis Therapeutics Reports Fourth Quarter and Full-Year 2016 Financial Results

BOULDER, Colo., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a pharmaceutical company historically focused on developing innovative solutions for people with...
January 12, 2017 16:10 ET | Source: Nivalis Therapeutics, Inc.

Nivalis Therapeutics Announces Corporate Restructuring

BOULDER, Colo., Jan. 12, 2017 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on developing innovative solutions for people with cystic...
January 03, 2017 18:00 ET | Source: Nivalis Therapeutics, Inc.

Nivalis Therapeutics Announces Review of Strategic Alternatives

BOULDER, Colo., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on developing innovative solutions for people with cystic...
November 28, 2016 16:05 ET | Source: Nivalis Therapeutics, Inc.

Nivalis Therapeutics Announces Results from Phase 2 Clinical Trial of Cavosonstat for Treatment of Cystic Fibrosis

BOULDER, Colo., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (“CF”), today...
November 14, 2016 16:05 ET | Source: Nivalis Therapeutics, Inc.

Nivalis Therapeutics Announces Completion of Enrollment in Second Phase 2 Study of Cavosonstat for Treatment of Cystic Fibrosis

- Study is Evaluating Cavosonstat in Patients Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated with Kalydeco™ - Data Expected in the First Quarter of 2017 BOULDER, Colo., Nov. ...
November 07, 2016 16:05 ET | Source: Nivalis Therapeutics, Inc.

Nivalis Therapeutics Reports Third Quarter 2016 Financial Results

BOULDER, Colo., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical-stage pharmaceutical company focused on treating people with cystic fibrosis (CF), today...
November 03, 2016 16:05 ET | Source: Nivalis Therapeutics, Inc.

Nivalis Therapeutics Announces Appointment of Cynthia Smith to Board of Directors

BOULDER, Colo., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on developing innovative solutions for people with cystic...
November 02, 2016 16:05 ET | Source: Nivalis Therapeutics, Inc.

Nivalis Therapeutics to Present at Two Upcoming Investor Conferences

BOULDER, Colo., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (CF), today...
September 06, 2016 07:30 ET | Source: Nivalis Therapeutics, Inc.

Nivalis Therapeutics to Present at Two Upcoming Investor Conferences

BOULDER, Colo., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (CF), today...